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ABSTRACT
Background. 5-HT3-receptor antagonists are one of the
mainstays of antiemetic treatment, and they are admin-
istered either i.v. or orally. Nevertheless, sometimes nei-
ther administration route is feasible, such as in patients
unable to admit oral intake managed in an outpatient
setting. Our objective was to evaluate the bioavailability
of s.c. granisetron.
Patients and Methods. Patients receiving platinum-
based chemotherapy were randomized to receive 3 mg
of granisetron either s.c. or i.v. in a crossover manner
during two cycles. Blood and urine samples were col-
lected after each cycle. Pharmacokinetic parameters
observed with each administration route were com-
pared by analysis of variance.
Results. From May to November 2005, 31 patients were
included and 25 were evaluable. Subcutaneous granis-
etron resulted in a 27% higher area under the concentra-
tion–time curve for 0–12 hours (AUC0–12h) and higher
levels at 12 hours, with similar values for AUC0–24h. The
maximum concentration was lower with the s.c. than with
the i.v. route and was observed 30 minutes following s.c.
administration.
Conclusion. Granisetron administered s.c. achieves
complete bioavailability. This is the first study that
shows that s.c. granisetron might be a valid alternative
to i.v. delivery. Further trials to confirm clinical equiv-
alence are warranted. This new route of administration
might be especially relevant for outpatient management
of emesis in cancer patients. The Oncologist 2007;12:
1151–1155
INTRODUCTION
Despite major improvements achieved in the management
of emesis, it still constitutes one of the most relevant side
effects of chemotherapy, and it is often underestimated by
physicians [1, 2]. The introduction of 5-hydroxytrypta-
mine-3-receptor antagonists (5-HT3RAs) has been one ma-
jor advance to treat and prevent emesis, and they are part of
standard antiemetic premedication for moderately and
highly emetogenic chemotherapy agents [3, 4]. Granisetron
(Kytril; Roche Laboratories, Inc., Nutley, NJ) is a potent
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and highly selective 5-HT3RA with weak antagonistic ac-
tion against other 5-HT3 receptors [5].
Because antiemetic drugs are administered either orally
or i.v., outpatient management of emesis remains a chal-
lenge when oral intake is limited by vomiting and i.v. ad-
ministration is not possible as a result of a lack of medical
staff and adequate equipment. The s.c. administration of
5-HT3RAs could be a valid alternative for these patients.
Theoretical advantages of the s.c. route over i.v. delivery
include its simplicity of use and its lower costs and fewer
complications. Although isolated clinical observations
have suggested the clinical efficacy of s.c. 5-HT3RAs, their
bioavailability has not been previously evaluated [6].
The aim of this study was to evaluate the bioavailability
of s.c. granisetron to assess if this route is a valid alternative
for cancer patients. We hypothesized that the bioavailabil-
ity of s.c. granisetron would not be inferior to that achieved
by i.v. delivery. In order to prove this hypothesis, we de-
signed a randomized crossover pharmacokinetic evaluation
of s.c. and i.v. granisetron.
PATIENTS AND METHODS
Cancer patients receiving platinum-based chemotherapy
were randomized to receive 3 mg of granisetron by either
s.c. or i.v. administration during the first cycle and to cross-
over to the alternative route during the second one. Ran-
domization was performed using random tables generated
before study approval. For i.v. treatment, 3 mg of granis-
etron was diluted in 50 ml of saline and administered over
10 minutes. For s.c. treatment, 3 mg of granisetron was ad-
ministered s.c. in the upper arm. Chemotherapy was the
same in both cycles for each patient. Patients received 20
mg of i.v. dexamethasone and further antiemetic treatment
if required, although administration of additional doses of
granisetron was not authorized, to avoid pharmacokinetic
interference. Additional inclusion criteria were: adequate
bone marrow, hepatic, and renal function, respectively de-
fined by: platelets 100,000/mm3 and absolute neutrophil
count 1,500/mm3; bilirubin, aspartate aminotransferase
and alanine aminotransferase 2 the upper limit of nor-
mal; and creatinine 1.5 mg/dl. Patients had to have an
Eastern Cooperative Oncology Group (ECOG) perfor-
mance status score 2 and body mass index of 20–28 kg/
m2. Patients were not eligible if they were pregnant or had
serious concomitant diseases. The main endpoint was bio-
availability (F). Although clinical efficacy was not an end-
point in this study, emesis was evaluated using a patient
self-assessment questionnaire in which patients recorded
the number of emetic episodes per day during the week fol-
lowing chemotherapy and the type and quantity of rescue
medication, and they were asked in which cycle they had
better control of emesis. Toxicity was assessed using Com-
mon Toxicity Criteria version 3.0 [7].
The protocol was approved by the appropriate ethics
committee and by the Spanish Agency for Medicines and
Healthcare Products. The Eudract number was 2004-
003877-10. All patients signed written informed consent
before treatment.
Pharmacokinetic Study
Blood samples (5 ml) were drawn before dosing and at 10,
15, 30, 45, and 60 minutes and 1.5, 2, 3, 4, 6, 8, 12, and 24
hours following granisetron administration. Ten-minute
and 24-hour samples were not collected in all patients. Ten-
minute samples were obtained once it had been confirmed
in the first patients that 15-minute samples were elevated
enough to make them informative. Twenty-four-hour sam-
ples were collected when it was possible, because as a result
of logistic reasons, patients were not always available at
this time. Blood was drawn in heparin tubes, centrifuged
(4°C, 3,000 r.p.m., 10 minutes) and frozen at 80°C until
analysis. Urine was collected for 12 hours after treatment.
An aliquot of urine was frozen at80°C until assay. Gran-
isetron levels were determined by high performance liquid
chromatography with fluorescence detection after liquid/
liquid extraction of acidified plasma samples. The quanti-
tation limit was 0.5 ng/ml. Calibration curves were
prepared at a concentration range of 0.5–100 ng/ml. Plasma
concentrations were analyzed by a Good Laboratory Prac-
tices–certified laboratory.
Maximum concentration (Cmax) and time to maximum
concentration (tmax) were obtained from experimental data.
Area under the concentration–time curve for 0–12 hours
(AUC0–12h) and AUC0–24h were calculated by the trapezoi-
dal rule. Half-life (t1/2) and terminal phase rate constant (ke)
were determined by unweighted nonlinear regression anal-
ysis of the terminal slope of the log plasma concentration–
time curve. Total plasma clearance (Cl) was calculated as
the ratio between dose and AUC0–24h, and volume of dis-
tribution (V) as the ratio between Cl and ke.
Statistical Analysis
Twenty-five patients were required to have a power of 0.80
to conclude bioequivalence at a significance level of 0.05 in
total bioavailability of s.c. administration in relation to i.v.
administration.
Pharmacokinetic parameters were compared by analy-
sis of variance (ANOVA) including the factors sequence,
period, formulation, and study participant to the log-trans-
formed parameters log(AUC) and log(concentration); the
relative bioavailability and the 90% confidence intervals
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(CIs) were estimated using the residual variance of the
ANOVA [8].
Other pharmacokinetic parameters were analyzed by
paired Student’s t-test or Wilcoxon test. Statistical analyses
were performed using SPSS 11.0 (SPSS Inc., Chicago, IL)
and WinNonlin Pro 4.1 (Pharsight Corporation, Mountain
View, CA).
RESULTS
From May to November 2005, 31 patients were included
and 25 of them were evaluable. Six patients were not evalu-
able because of an incorrect dose of granisetron (one pa-
tient), volunteer decision to leave the study (three patients),
and treatment discontinuation because of disease progres-
sion (two patients). Patient characteristics were: 20 men/5
women; mean age, 56 years (standard deviation [SD], 9.3);
and mean body mass index, 25.6 kg/m2 (SD, 4.1). All pa-
tients were diagnosed with non-small cell lung cancer.
From 23 patients evaluable for antiemetic symptoms, 15 re-
ported no differences between the two cycles, six had less
emesis with s.c. granisetron, and two presented better con-
trol with the i.v. route. No adverse events related to granis-
etron were observed. s.c. granisetron did not produce local
skin reactions.
Pharmacokinetic parameters are presented in Table 1.
Following i.v. administration, Cmax was observed at the end
of the infusion. However, after s.c. administration, Cmax
was reached after 30 minutes. As expected, the Cmax value
was 48%–68% lower with s.c. than with i.v. administration.
Mean plasma concentrations of granisetron are shown in
Figure 1. The s.c. administration of granisetron produced a
27% higher AUC0–12h (90% CI, 7%–74%) than with i.v.
delivery and higher concentrations at 12 and 24 hours. No
statistically significant differences were seen in AUC0–24h
or urinary elimination between the two routes, indicating
similar bioavailability with a relative F of 1.0339 (103%).
Other pharmacokinetic parameters (t1/2, Cl, V) were not sta-
tistically different.
DISCUSSION
The availability of oral 5-HT3RAs has facilitated outpatient
management of emesis. Oral granisetron has adequate bio-
availability and shows comparable efficacy and tolerability
with i.v. 5-HT3RAs [9–11]. However, the use of oral anti-
emetics is impaired when heavy vomiting precludes their
intake, and often, i.v. administration is not possible in an
outpatient setting. We have shown that the s.c. administra-
tion of granisetron has similar bioavailability to that of i.v.
delivery, achieving an even higher AUC0–12h, and seems,
therefore, to be a valid alternative route to administer this
drug.
The use of higher granisetron doses has not been proven
to be superior to doses of 1 mg [12–14]. We used a 3-mg
dose to improve our ability to detect adequate plasma lev-
els, and therefore to achieve valid conclusions, because
granisetron pharmacokinetics appear to be independent of
dose in the range of 1–24 mg [15].
Cmax values of 13.8–39.8 ng/ml have been previously
observed following i.v. administration of 3 mg of granis-
etron for a 0.5- to 1-hour infusion [16]. By the oral route, 1
Table 1. Pharmacokinetic characteristics of s.c. and i.v. granisetron, compared by Student’s t-test for paired samples and
Wilcoxon test
i.v.
(mean SD) n i.v.
s.c.
(mean SD) n s.c. p-value
AUC0–12h (g hours/l) 101.7 56.7 21 128.4 69.5 22 .029
AUC0–24h (g hours/l) 179.4 100.3 10 185.5 113.2 10 NS
Cmax (g/l) 72.4 35.8 27 43.7 33.2 28 .001
tmax (hours) NA NA 0.456 0.26 28 NA
ke (1/hour) 0.169 0.285 25 0.137 0.095 26 NSa
t1/2 (hours) 11.3 10.6 25 7.9 5.6 26 NSa
V (l) 274.1 193.5 27 218.9 140.2 28 NS
Cl (l/hour) 34.2 49.7 27 35.1 68.7 28 NSa
C12h (g/l) 4 3.1 21 5.4 3.4 22 .031a
C24h (g/l) 3.5 2.7 10 3.6 2.4 11 .028
Ae12h (mg) 0.902 0.594 23 0.954 0.698 23 NSa
aWilcoxon’s test.
Abbreviations: Ae, amount of granisetron eliminated by urine; AUC, area under the concentration–time curve; C,
concentration; Cl, clearance; Cmax, maximum concentration; ke, elimination constant; NA, not applicable; NS, not
statistically significant; t1/2, half-life; tmax, time to maximum concentration; V, distribution volume.
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mg of granisetron achieved Cmax values of 7.42 and 8.8
ng/ml [17]. A rapid i.v. infusion of 3 mg of granisetron over
30 seconds produced a concentration of 233 ng/ml [18]. We
observed a granisetron level of 43.7 ng/ ml following s.c.
administration, which is consistent with the values reported
in these studies, considering differences in dose and infu-
sion rate. Moreover, the elimination t1/2 values observed in
our study for the s.c. and i.v. routes were, respectively, 7.9
hours and 11.3 hours, also in the range of previously re-
ported results, 1.63–11.7 hours [19, 20]. The differences
observed in Cmax between the two administration routes are
unlikely to affect clinical efficacy, because they were only
observed over a short time period of around 5 minutes. In
addition, as mentioned above, higher doses of granisetron
have not been proven to have greater clinical efficacy than
lower doses. As for differences in tmax, it is also unlikely
that they may affect clinical efficacy in the setting of pre-
vention, because antiemetics are given several minutes be-
fore chemotherapy. Nonetheless, this difference may be
relevant for treatment of emesis that is already ongoing, be-
cause tmax is achieved faster with i.v. administration.
Subcutaneous granisetron showed complete bioavail-
ability, similar to i.v. treatment, as confirmed by the fact
that the AUC0–24h of the former was 102.1% of the latter
(90% CI, 100.6%–131.1%). This was confirmed by the uri-
nary clearance, which was not statistically different be-
tween the two routes. As expected, no differences were
observed in t1/2, V, or Cl, because the drug administered
was the same. Intravenous administration achieved a higher
Cmax than s.c. delivery as a result of the zero-order absorp-
tion process. The Cmax was observed 30 minutes (range,
10–60 minutes) after s.c. administration. In comparison,
tmax occurred 180 minutes after oral administration [19].
Granisetron concentrations at 12 hours were 40% higher af-
ter s.c. than after i.v. administration. The difference in
AUC0–12h is probably related to the slow s.c. absorption.
Chaturvedula et al. [21] observed a subdermal depot forma-
tion of granisetron following application of iontophoretic
cutaneous patches. This depot was responsible for pro-
longed absorption and for the high plasma concentrations
observed. Another report showed that one elimination route
of granisetron is back diffusion into the bloodstream from a
peripheral compartment [16]. If so, a slow and continuous
infusion of granisetron would retard its disappearance from
the blood and increase AUC values in patients when gran-
isetron is administered s.c. Nonetheless, the observed dif-
ferences in AUC between the two administration routes
would be likely to disappear, or even to favor i.v. delivery,
if the pharmacokinetic assessment had been performed over
a more prolonged time period.
SUMMARY
The s.c. administration of granisetron has similar bioavail-
ability to i.v. delivery, achieving an even higher AUC0–12 h.
This is the first study that shows that s.c. granisetron might
be a valid alternative to its i.v. use. This new route of ad-
ministration might be especially relevant for outpatient
management of emesis in cancer patients. Further studies
are warranted to confirm the clinical efficacy of s.c. gran-
isetron.
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Figure 1. Granisetron mean plasma levels ( standard devi-
ation) following a single 3-mg dose i.v. or s.c. (A): First 24
hours, semilogarithmic graph. (B): First 2 hours.
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